GRANT OF SURVIVAL ANALYSIS adjuvant chemotherapy oxaliplatin BASED ON CANCER PATIENTS IN KOLON DR Sardjito
ABSTRACT: Background. Oxaliplatin is a standard treatment of high risk stage II and stage III colon cancer in many countries. It has been given since 2007 in our routine clinical practice. However, its efficacy and safety has not been assessed. We wanted to evaluate the efficacy and safety of oxaliplatin therapy. Objectives. The primary endpoint of this study was to assess overall survival (OS) of resectable colon cancer in our routine clinical practice. The secondary endpoint was to assess disease free survival (DFS) and the toxicity of oxaliplatin therapy. Methods. Data of high risk stage II and stage III colon cancer receiving adjuvant oxaliplatin therapy setting between January 1, 2007 and April 30, 2016 was retrospectively reviewed. OS and DFS were calculated using Kaplan-Meier method. The toxicities are presented in frequencies. Results. 88 samples of this study had been analysed at a median follow-up of 25,21 months. The estimated overall survival (OS) rates at 2 years were 75,8% and estimated disease free survival (DFS) at 2 years were 72,7% among patients receiving oxaliplatin. No significant differences in OS were found based on aged group, interval between resection to chemotherapy, and regimen based. Locoregional spread was the common modes of recurrence at 62.9%. The study showed that surgery involving adequate lymph node examination (> 10 lymph nodes) were only 9,5% of the total patients. The incidence of neuropathy in oxaliplatin administration amounted to 28.4% Conclusion. Colon cancer treated with adjuvant oxaliplatin in our routine clinical practice had 2-year OS at 75,8% and 2-year DFS at 72,7%. The large amount of locoregional recurrence shows the importance of good quality surgery to detract recurrences and improve survival. The incidence of neuropathy as common specific toxicity were under reported.
